Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Cancer Pain

Alabama

Birmingham : Global Clinical Trial Link, LLC

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Arizona

Casa Grande : Desert Oasis Cancer Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Phoenix : Redpoint Research

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

California

Fountain Valley : Pacific Coast Hematology/Oncology Medical Group, Inc.

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Gilroy : Office of Dr. Ronald Yanagihara

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Loma Linda : Center for Pain Management

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Los Angeles : UCLA

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Montebello : Clinical Trials and Research Associates, Inc.

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

San Diego : University of California San Diego Medical Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Florida

Jacksonville : Florida Institute of Medical Research

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Lakeland : Lakeland Regional Cancer Center

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Sarasota : Sarasota Pain Medicine Research

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Sarasota : Lovelace Scientific Resources, Inc.

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Tampa : Moffitt Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Tampa : University of Southern Florida

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Winter Park : National Pain Research Institute, LLC

A Multi-Center Study to Evaluate the Safety and Efficacy an Investigational Medication for the Treatment of Breakthrough Cancer Pain

Georgia

Decatur : Dekalb Pain Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Marietta : Drug Studies America, Inc.

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Riverdale : Center of Hope for Cancer and Blood Disorders

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Illinois

Springfield : Southern Illinois University School of Medicine

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Kansas

Overland Park : International Clinical Research Institute

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Kentucky

Lexington : The Pain Treatment Center of the Bluegrass

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Louisiana

New Orleans : Louisiana Research Associates

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Shreveport : WillisKnight River Cities Clinical Research Center

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Maryland

Hagerstown : Research Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Massachusetts

Boston : Brigham and Women's Hospital

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Burlington : Lahey Clinic

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Chestnut Hill : Brigham and Women's Hospital

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Fall River : St. Anne's Hospital New!

“A PIVOTAL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF MR-GUIDED FOCUSED ULTRASOUND TREATMENT OF METASTATIC BONE TUMORS FOR THE PALLIATION OF PAIN IN PATIENTS WHO ARE NOT CANDIDATES FOR RADIATION THERAPY.”

Minnesota

Edina : MAPS Applied Research Center (MARC)

Breakthrough Cancer Pain Study

Edina : MAPS Applied Research Center (MARC)

Cancer Induced Bone Pain Study

Missouri

Jefferson City : Capital Comprehensive Cancer Care Clinic

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Kansas City : St. Luke's Cancer Institute

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

St. Louis : A & A Pain Institute

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Montana

Great Falls : Research Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

New Jersey

Vorhees : Virtua Health

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

New York

New York : Memorial Sloan Kettering Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

New York : Cornell University

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

North Carolina

Flat Rock : Four Seasons Hospice & Pallative Care

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Flat Rock : Four Seasons Hospice & Pallative Care

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Winston-Salem : Center for Clinical Research

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Winston-Salem : Center for Clinical Research

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Ohio

Akron : Summa Health System/ Cancer Research

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Canton : Gabrail Cancer Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Canton : Gabrail Cancer Center

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Dover : Gabrail Cancer Center

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Oklahoma

Oklahoma City : Oklahoma Gynecologic Oncology

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Pennsylvania

Philadelphia : Fox Chase Cancer Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

South Carolina

Sumter : Office of Billy Clowney

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Texas

Austin : Lone Star Oncology

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Houston : The Methodist Hospital Research Institute

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Houston : Research Concepts, Ltd.

This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating.

Utah

Salt Lake City : Huntsman Cancer Institute

Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)

Canada

Toronto, Ontario : Toronto General Hospital

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Israel

Haifa : Rambam Medical Center - Pain Palliaton Unit

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Tel Hashomer : Sheba Medical Center

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy

Russia

St. Petersberg : N. N. Petrov Institute of Oncology

A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment (Magnetic Resonance-guided Focused Ultrasound) of Metastatic Bone Tumors or Multiple Myeloma for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy